BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary ...

TradeStation Securities is teaming up with TipRanks to allow retail investors to trade stocks and equity options directly through the TipRanks platform, ...